Global Market Access

Key Details

WHERE

Barcelona

AVERAGE AGE

23-24 years old

DURATION

10 Months. Full Time

STARTING DATE

October 2021

LANGUAGE

English

AVERAGE WORK EXPERIENCE

None to 2 years

CULTURAL DIVERSITY

> 15 Nationalities

EMPLOYMENT

96% of the students within the year

This programme will take you through the path of new drug approvals

The objective of the master program is to understand the process of how the industry prepares a new global drug approval entry and the global value dossier to work with the administrations and governments to deliver it to the patients

Work closely with to the administrations in order to launch new compounds


The main roles and companies related with these areas of knowledge’s are those such as, global and local market access manager, government affairs, pricing and value management or patient advocacy, among other corporate positions at biotechnology-based companies, the pharmaceutical industry and other companies related to healthcare. 

VIEW ALUMNI REPORT

Programme Syllabus

  • add_circle_outline1st Semester Module I - Management in Biotechnology

    10 ECTS credits

    • • Early-stage innovation & Licensing Agreements. During this first course you will acquire the bases of innovation and technology transfer processes, as well as understanding the type of licensing agreements and the strategic approach.

    • • Venture Capital and Biotechnology Based Companies. This part of the course will give you and global overview of the financial markets and more specifically the biotech market. The aim is to acquire a solid financial base in private funding.

    • • Market Access and Health Economics. This introductory module will give you a deep overview on the main analysis and value dossiers, between the private industry and the national healthcare systems and the strategic design for accessing new drugs.

    • • Project Management. The focus of this part of the module is learning about how a global perceptive in management and team leadership is necessary in global companies to achieve goals due portfolio management and new compounds.

  • add_circle_outline1st Semester Module II - Scientific & Regulatory Development

    10 ECTS credits

  • add_circle_outline1st Semester Module III - Global Pharmaceutical Industry

    10 ECTS credits

  • add_circle_outline2nd Semester Module IV - Pricing

    10 ECTS credits

    • • Lesson 1. Pricing basics

    • • Lesson 2. Premium Price and Shared risks

    • • Lesson 3. Real World Evidence

    • • Lesson 4. QUALY Adjustment

  • add_circle_outline2nd Semester Module V - Pharmacoeconomics I

    10 ECTS credits

    • • Lesson 1. Cost of Disease Design

    • • Lesson 2. Business Development and the Industry

    • • Lesson 3. National Healthcare Systems

    • • Lesson 4. Patients Associations

  • add_circle_outline2nd Semester Module VI - Pharmacoeconomics II

    10 ECTS credits

    • • Lesson 1. Price Negotiations

    • • Lesson 2. Reference Pricing & Pricing Strategy

    • • Lesson 3. Consulting

    • • Lesson 4. Health Evaluation

  • add_circle_outline2nd Semester Module VII - Market Access

    10 ECTS credits

    • • Lesson 1. Global Market Access Strategy

    • • Lesson 2. Strategic market access - HTA

    • • Lesson 3. Emerging Markets & Healthcare

    • • Lesson 4. Government Affairs

  • add_circle_outlineModule VIII - Sc. MBA Thesis Project

    15 ECTS credits

    • • Global Market Access & Pricing Strategy.

  • add_circle_outlineModule IX - Career Impact Program

    5 ECTS credits

Industry relationships with national healthcare systems are the core of the MBA


Some of the areas of knowledge that will be develop during the MBA in Global Market Access involve, Premium Price and Shared risks, Real World Evidence, Price Negotiations, Reference Pricing & Pricing Strategy, Strategic market access - HTA and Government Affairs.

 

DISCOVER YOUR CAREER OPPORTUNITIES

MEET OUR VISITING LECTURERS

Testimonials

The Sc.MBA in Global Market Access will allow our studetns to have and applied understanding of the processes involved in new drug approvals and the relationship with the national governments in order to introduce new drugs for patients

Nerea Blanqué - Vice President Market Access and Pricing at Alira Health

The Sc.MBA in Global Market Access has allowed me to increase my specific knoweldge in the new drug approvals scene and has given me the tools to continue developing my career in this particular field

Maria Cavaller - Patient Engagement at EURORDIS - Rare Diseases Europe & BBI Alumni

"The master gave me a vision of the whole drug lifecycle, from early development stages until it is launched to the market. BBI also helped me to develop the necessary skills to work in the healthcare sector and, consequently, successfully start my career. "

Marta Aguado - HEOR Analyst at AliraHeatlh

Apply online

Your Business School
for Scientific Management